Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TYMS opposite strand RNA (TYMSOS), also known as C18orf56, is a long noncoding RNA (lncRNA) gene located on chromosome 18 in humans[3][7]. It is not a receptor, enzyme, transporter, or classical drug target. Instead, it has been shown to regulate gene expression, with research particularly implicating it in the promotion of epithelial-mesenchymal transition (EMT) and metastasis in thyroid carcinoma, acting through modulation of MARCKSL1 and activation of the PI3K pathway[5][7][8]. There is no current evidence for approved drugs interacting directly with TYMSOS, nor is it established as a clinical biomarker or target with defined mechanisms of action for approved therapeutics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TYMS opposite strand RNA (TYMSOS).